Charles Schwab
GRTX

Charles Schwab’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

Charles Schwab’s Portfolio GRTX Stock Details GRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-16,362
Closed -$51K – 3653
2023
Q2 		$51K Buy
+16,362
New +$48.7K ﹤0.01% 3418
2021
Q2 		– Sell
-22,894
Closed -$202K – 3562
2021
Q1 		$202K Buy
22,894
+4,061
+22% +$44.6K ﹤0.01% 3320
2020
Q4 		$193K Hold
18,833
– – ﹤0.01% 3262
2020
Q3 		$171K Hold
18,833
– – ﹤0.01% 3201
2020
Q2 		$135K Buy
+18,833
New +$200K ﹤0.01% 3221

Other funds holding GRTX

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Charles Schwab's GRTX Position: Q3 2023 in Review

Charles Schwab sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q3 2023, closing a stake of 16,362 shares — an estimated $51K sold.

Charles Schwab first reported a position in GRTX in Q2 2020 and held it in 5 quarters. The position peaked at $202K in Q1 2021. 38 funds tracked by Wall St. Rank hold GRTX as of Q3 2023.

  • Charles Schwab reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Charles Schwab sold 16,362 Galera Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $51K.
  • Charles Schwab first reported a position in Galera Therapeutics, Inc. Common Stock in Q2 2020 and held it in 5 quarters.
  • Charles Schwab's Galera Therapeutics, Inc. Common Stock position peaked at $202K in Q1 2021.
  • 38 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Charles Schwab's 13F filing for Q3 2023, filed 8 Nov 2023.